Plain-English translation of NCT04504123 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether doxycycline, a low-dose antibiotic, can help improve vision in people with wet age-related macular degeneration (a serious eye disease) who are not getting enough benefit from their regular eye injections. Researchers believe this medication may reduce inflammation in the eye and help the standard treatments work better. You would take the medication or a placebo by mouth once a day for 6 months while continuing your regular eye care.
Some people with wet macular degeneration continue to have fluid buildup in their eyes even after receiving multiple standard injection treatments. This trial is testing whether adding this medication might help reduce that stubborn fluid and improve vision in these cases.
You likely qualify if…
You likely don't qualify if…
You would visit your eye clinic every 3 months for 9 months total. Half of participants will receive the medication as a daily capsule, and half will receive a placebo (inactive pill)—neither you nor your doctor will know which you're taking. During these visits, you'll have standard eye imaging (OCT scans) and vision tests as part of your normal care, plus some extra blood work and a small eye fluid sample at the start, middle, and end of the study. You'll also answer brief questions about how your vision affects your daily life and any side effects you experience.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
United States